Clinical trial
A Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Dose-Range Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT07474792 is registered in ClinicalTrials.gov with Oruka Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Dose-Range Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
- Lead sponsor
- Oruka Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- March 19, 2026
- Completion date
- April 30, 2029
- Enrollment
- 160 (estimated)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.
plaque psoriasis